Ataxia

>

The NeurologyLive® Ataxia Disease Spotlight page provides in-depth updates and specific coverage on the latest data readouts and expert conversations related to the treatment and management of patients with the movement disorder.

Latest News

New Postmarketing Registry to Evaluate Real-World Safety and Patient Experience With Omaveloxolone
New Postmarketing Registry to Evaluate Real-World Safety and Patient Experience With Omaveloxolone

November 19th 2024

The SKYCLARYS PASS registry, an international observational cohort study, aims to include approximately 300 omaveloxolone-naïve patients participating in the Friedreich’s Ataxia Global Consortium's UNIFIED natural history study.

NeurologyLive® Brain Games: November 17, 2024
NeurologyLive® Brain Games: November 17, 2024

November 17th 2024

Gastrointestinal Disorders and Aminotransferase Elevations Cited as Most Noted Adverse Events of Omaveloxolone
Gastrointestinal Disorders and Aminotransferase Elevations Cited as Most Noted Adverse Events of Omaveloxolone

November 16th 2024

Subgroup Analyses Give Weight for Next-Level Trial of GV1001 in Progressive Supranuclear Palsy
Subgroup Analyses Give Weight for Next-Level Trial of GV1001 in Progressive Supranuclear Palsy

November 8th 2024

PTC to Submit NDA for Vatiquinone in Friedreich Ataxia Following Positive Long-Term Extension Data
PTC to Submit NDA for Vatiquinone in Friedreich Ataxia Following Positive Long-Term Extension Data

October 8th 2024

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.